Literature DB >> 22094876

Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets.

Vijay R Dondeti1, Bradley Wubbenhorst, Priti Lal, John D Gordan, Kurt D'Andrea, Edward F Attiyeh, M Celeste Simon, Katherine L Nathanson.   

Abstract

Sporadic clear cell renal cell carcinoma (ccRCC), the most common type of adult kidney cancer, is often associated with genomic copy number aberrations on chromosomes 3p and 5q. Aberrations on chromosome 3p are associated with inactivation of the tumor suppressor gene von-Hippel Lindau (VHL), which activates the hypoxia-inducible factors HIF1α and HIF2α. In contrast, ccRCC genes on chromosome 5q remain to be defined. In this study, we conducted an integrated analysis of high-density copy number and gene expression data for 54 sporadic ccRCC tumors that identified the secreted glycoprotein STC2 (stanniocalcin 2) and the proteoglycan VCAN (versican) as potential 5q oncogenes in ccRCCs. In functional assays, STC2 and VCAN each promoted tumorigenesis by inhibiting cell death. Using the same approach, we also investigated the two VHL-deficient subtypes of ccRCC, which express both HIF1α and HIF2α (H1H2) or only HIF2α (H2). This analysis revealed a distinct pattern of genomic aberrations in each group, with the H1H2 group displaying, on average, a more aberrant genome than the H2 group. Together our findings provide a significant advance in understanding ccRCCs by offering a molecular definition of two subtypes with distinct characteristics as well as two potential chromosome 5q oncogenes, the overexpression of which is sufficient to promote tumorigenesis by limiting cell death. ©2011 AACR

Entities:  

Mesh:

Year:  2011        PMID: 22094876      PMCID: PMC3251639          DOI: 10.1158/0008-5472.CAN-11-1698

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 2.  Renal cell carcinoma: where will the state-of-the-art lead us?

Authors:  A Rose Brannon; W Kimryn Rathmell
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

Review 3.  VHL and HIF signalling in renal cell carcinogenesis.

Authors:  Marcella M Baldewijns; Iris J H van Vlodrop; Peter B Vermeulen; Patricia M M B Soetekouw; Manon van Engeland; Adriaan P de Bruïne
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

4.  Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma.

Authors:  Jianming Pei; Madelyn M Feder; Tahseen Al-Saleem; Zemin Liu; Angen Liu; Gary R Hudes; Robert G Uzzo; Joseph R Testa
Journal:  Genes Chromosomes Cancer       Date:  2010-07       Impact factor: 5.006

5.  The histone demethylase UTX enables RB-dependent cell fate control.

Authors:  Jordon K Wang; Miao-Chih Tsai; Gino Poulin; Adam S Adler; Shuzhen Chen; Helen Liu; Yang Shi; Howard Y Chang
Journal:  Genes Dev       Date:  2010-02-01       Impact factor: 11.361

6.  Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.

Authors:  Kenji Tamura; Mutsuo Furihata; Su-Yong Chung; Motohide Uemura; Hiroki Yoshioka; Tatsuo Iiyama; Shingo Ashida; Yasutomo Nasu; Tomoaki Fujioka; Taro Shuin; Yusuke Nakamura; Hidewaki Nakagawa
Journal:  Cancer Sci       Date:  2009-02-26       Impact factor: 6.716

7.  Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.

Authors:  Michael L Nickerson; Erich Jaeger; Yangu Shi; Jeffrey A Durocher; Sunil Mahurkar; David Zaridze; Vsevolod Matveev; Vladimir Janout; Hellena Kollarova; Vladimir Bencko; Marie Navratilova; Neonilia Szeszenia-Dabrowska; Dana Mates; Anush Mukeria; Ivana Holcatova; Laura S Schmidt; Jorge R Toro; Sara Karami; Rayjean Hung; Gary F Gerard; W Marston Linehan; Maria Merino; Berton Zbar; Paolo Boffetta; Paul Brennan; Nathaniel Rothman; Wong-Ho Chow; Frederic M Waldman; Lee E Moore
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

8.  The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.

Authors:  Vincenzo Ficarra; Giacomo Novara; Antonio Galfano; Matteo Brunelli; Stefano Cavalleri; Guido Martignoni; Walter Artibani
Journal:  BJU Int       Date:  2008-09-08       Impact factor: 5.588

9.  Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.

Authors:  Tobias Klatte; P Nagesh Rao; Michela de Martino; Jeffrey LaRochelle; Brian Shuch; Nazy Zomorodian; Jonathan Said; Fairooz F Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

10.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

Authors:  John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A Greenberg; Keith T Flaherty; W Kimryn Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

View more
  28 in total

Review 1.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.

Authors:  Yozo Mitsui; Hiroaki Shiina; Taku Kato; Shigekatsu Maekawa; Yutaka Hashimoto; Marisa Shiina; Mitsuho Imai-Sumida; Priyanka Kulkarni; Pritha Dasgupta; Ryan Kenji Wong; Miho Hiraki; Naoko Arichi; Shinichiro Fukuhara; Soichiro Yamamura; Shahana Majid; Sharanjot Saini; Guoren Deng; Rajvir Dahiya; Koichi Nakajima; Yuichiro Tanaka
Journal:  Mol Cancer Res       Date:  2017-02-27       Impact factor: 5.852

Review 3.  Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway?

Authors:  Gabriele Grasmann; Elisabeth Smolle; Horst Olschewski; Katharina Leithner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

4.  Identification of functional cooperative mutations of SETD2 in human acute leukemia.

Authors:  Xiaofan Zhu; Fuhong He; Huimin Zeng; Shaoping Ling; Aili Chen; Yaqin Wang; Xiaomei Yan; Wei Wei; Yakun Pang; Hui Cheng; Chunlan Hua; Yue Zhang; Xuejing Yang; Xin Lu; Lihua Cao; Lingtong Hao; Lili Dong; Wei Zou; Jun Wu; Xia Li; Si Zheng; Jin Yan; Jing Zhou; Lixia Zhang; Shuangli Mi; Xiaojuan Wang; Li Zhang; Yao Zou; Yumei Chen; Zhe Geng; Jianmin Wang; Jianfeng Zhou; Xin Liu; Jianxiang Wang; Weiping Yuan; Gang Huang; Tao Cheng; Qian-Fei Wang
Journal:  Nat Genet       Date:  2014-02-09       Impact factor: 38.330

Review 5.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

Review 6.  Hereditary kidney cancer syndromes.

Authors:  Naomi B Haas; Katherine L Nathanson
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

Review 7.  Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

Authors:  Achilleas D Theocharis; Chrisostomi Gialeli; Panagiotis Bouris; Efstathia Giannopoulou; Spyros S Skandalis; Alexios J Aletras; Renato V Iozzo; Nikos K Karamanos
Journal:  FEBS J       Date:  2014-11-06       Impact factor: 5.542

8.  The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Authors:  Toni K Choueiri; André P Fay; Robert Gagnon; Ying Lin; Brittany Bahamon; Victoria Brown; Jonathan E Rosenberg; Thomas E Hutson; Katherine L Baker-Neblett; Christopher Carpenter; Yuan Liu; Lini Pandite; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

9.  Computational repositioning and preclinical validation of pentamidine for renal cell cancer.

Authors:  Luiz Fernando Zerbini; Manoj K Bhasin; Jaira F de Vasconcellos; Juliano D Paccez; Xuesong Gu; Andrew L Kung; Towia A Libermann
Journal:  Mol Cancer Ther       Date:  2014-05-01       Impact factor: 6.261

10.  PBRM1 and BAP1 as novel targets for renal cell carcinoma.

Authors:  James Brugarolas
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.